Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in Metastatic Renal Cell Carcinoma or Muscle Invasive Bladder Cancer
NCT03473730Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2018
- Primary completion
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of daratumumab in metastatic renal cell carcinoma (mRCC) and muscle-invasive bladder cancer (MIBC) (2 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of adverse events, Rate of surgical delay and 1 more. Started May 2018; status: completed.
02
Drugs
daratumumab
03
Conditions
metastatic renal cell carcinoma (mRCC)muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT03473730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03473730.